DNLI - Denali Therapeutics Inc.
| Previous Close | 19.55 |
| Open | 19.73 |
| Bid | 19.98 x 900 |
| Ask | 20.16 x 1400 |
| Day's Range | 19.60 - 20.69 |
| 52 Week Range | 12.32 - 28.86 |
| Volume | 107,013 |
| Avg. Volume | 400,885 |
| Market Cap | 1.932B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.60 |
- Zacks•6 days ago
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
- GlobeNewswire•7 days ago
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that the FDA granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for Denali’s DNL310 program, which Denali is developing for patients with mucopolysaccharidosis II (“MPS II” or Hunter Syndrome). DNL310, or ETV:IDS, is a recombinant form of the iduronate 2-sulfatase (“IDS”) enzyme engineered to cross the blood-brain barrier (“BBB”) using Denali’s proprietary ETV technology.
- Zacks•last month
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -10.81% and -67.35%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•last month
Denali Therapeutics Reports First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- Zacks•2 months ago
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- American City Business Journals•2 months ago
Controversial Alzheimer's Disease theory could pinpoint new drug targets
Some scientists believe Alzheimer's is a prions-like disease but is not a prions disease as identified by Nobel Prize-winning UCSF researcher Dr. Stanley Prusiner.
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of December 31. The results of that effort will be put on display in this article, as […]
- American City Business Journals•2 months ago
Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon.
- Motley Fool•2 months ago
3 Biotech Stocks That Doubled After Hitting Bottom in 2018
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
- Simply Wall St.•3 months ago
Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boo...
- Zacks•3 months ago
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 4050.00% and 1191.24%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•3 months ago
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., March 12, 2019 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
- GlobeNewswire•4 months ago
New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
“We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS penetration, and target engagement, at the studied doses.” said Carole Ho, M.D., Chief Medical Officer of Denali. “Similar to our previously announced Phase 1b study in ALS, the primary purpose of this Phase 1b study is to gain additional safety and biomarker data in patients with Alzheimer’s disease to support dose selection.
- American City Business Journals•5 months ago
Genentech kills big drug study in early Alzheimer's patients
Genentech's Alzheimer's-fighting drug failed two late-stage studies, but other Bay Area companies are continuing with different approaches to the memory-stealing disease.
- GlobeNewswire•5 months ago
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
“Based on Phase 1 data in healthy volunteer subjects demonstrating DNL747’s excellent CNS penetration, safety profile, and ability to inhibit the RIPK1 pathway, we are excited to evaluate DNL747 in ALS patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “The primary purpose of this Phase 1b study is to gain additional safety and biomarker data in ALS patients to support dose selection.
- GlobeNewswire•6 months ago
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
“Based on the positive outcome of our Phase 1 study in 122 healthy volunteer subjects, we are excited to evaluate DNL201 in Parkinson’s disease patients,” said Carole Ho, M.D., Chief Medical Officer of Denali. “This study will provide additional important safety and biomarker data in patients to support rational dose selection.
- Benzinga•6 months ago
The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral downturn. New molecular entity approval hit a new peak at 55 thus far ...
American City Business Journals•7 months agoHealth Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.
- Benzinga•7 months ago
The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
- GlobeNewswire•7 months ago
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1). RIPK1 is a critical signaling protein in the tumor necrosis factor receptor pathway and is a regulator of inflammation and cell death in tissues throughout the body. Denali recently announced a broad collaboration with Sanofi on the development of multiple RIPK1 inhibitor molecules, including DNL747, to study their potential to treat a range of neurological and systemic inflammatory diseases.
- American City Business Journals•7 months ago
Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
- GlobeNewswire•7 months ago
Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
SOUTH SAN FRANCISCO, Nov. 08, 2018 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for.
